Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera

127Citations
Citations of this article
120Readers
Mendeley users who have this article in their library.

Abstract

After decades of Alzheimer's disease (AD) research, the development of a definitive diagnostic test for this disease has remained elusive. The discovery of blood-borne biomarkers yielding an accurate and relatively non-invasive test has been a primary goal. Using human protein microarrays to characterize the differential expression of serum autoantibodies in AD and non-demented control (NDC) groups, we identified potential diagnostic biomarkers for AD. The differential significance of each biomarker was evaluated, resulting in the selection of only 10 autoantibody biomarkers that can effectively differentiate AD sera from NDC sera with a sensitivity of 96.0% and specificity of 92.5%. AD sera were also distinguishable from sera obtained from patients with Parkinson's disease and breast cancer with accuracies of 86% and 92%, respectively. Results demonstrate that serum autoantibodies can be used effectively as highly-specific and accurate biomarkers to diagnose AD throughout the course of the disease. © 2011 Nagele et al.

Cite

CITATION STYLE

APA

Nagele, E., Han, M., DeMarshall, C., Belinka, B., & Nagele, R. (2011). Diagnosis of Alzheimer’s disease based on disease-specific autoantibody profiles in human sera. PLoS ONE, 6(8). https://doi.org/10.1371/journal.pone.0023112

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free